eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
2/2008
vol. 33
 
Share:
Send email
Share:
abstract:

Clinical immunology
The effect of a single dose of enoxaparine on the angiogenic potential of human serum and plasma

Leszek Jung
,
Joanna Chorostowska-Wynimko
,
Ewa Skopińska-Różewska
,
Andrzej K. Siwicki
,
Marcin Skorupski
,
Ewa Sommer
,
Barbara J. Bałan
,
Adriana Roży
,
Aleksander Wasiutyński

(Centr Eur J Immunol 2008; 33 (2): 50-53)
Online publish date: 2008/05/05
View full text Get citation
 
Enoxaparine (En) – the low-molecular weight heparin (LMW) is routinely used as anti-coagulant in the thrombo-embolic prophylaxis prior to and following any surgical intervention. Our preliminary observations demonstrated that single enoxaparine dose administered prior to the hip surgery resulted in the increased angiogenic activity and basic fibroblast growth factor (bFGF) levels in patients’ sera without any corresponding alterations in the vascular endothelial growth factor (VEGF) concentration.
The aim of the present study was to further analyze the mechanism of En proangiogenic effect. Plasma and serum samples have been collected from 12 patients prior to the hip surgery – before and 12 hours following single enoxaparine (40 mg) dose. In both materials serum and plasma, increased in vivo angiogenic activity has been demonstrated in the mouse cutaneous test following En administration. Also, plasminogen activator inhibitor-1 (PAI-1) levels increased while insulin-like growth factor-1 (IGF-1) concentrations decreased after single enoxaparine dose. No significant alterations in plasma VEGF, fibrinogen and antithrombin III levels were seen.
keywords:

enoxaparine, angiogenesis, IGF-1, VEGF, PAI-1, fibrinogen, AT-III
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.